[Federal Register Volume 67, Number 57 (Monday, March 25, 2002)]
[Notices]
[Page 13643]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-7057]



[[Page 13643]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: The Use of Macrocyclic 
Lactones as Inhibitors of Vacuolar-Type ATPases for the Treatment of 
Cancer

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the invention embodied in: 60/122,953 
filed 3/5/99 (Provisional I, DHHS ref. No. E-244-97/2); 60/169,564 
filed 12/8/99 (Provisional II, DHHS ref. No. E-244-97/0) and PCT (PCT/
US00/05582), filed 3/3/00 and claiming priority to both Provisionals I 
and II, ``Vacuolar-Type (H\+\) ATPase Inhibiting Compounds, 
Compositions and Uses Thereof;'' and 60/053,784, filed 7/25/97 (DHHS 
Ref. No. E-244-97/1), converted into PCT/US98/15011 filed 7/23/98, 
``Antitumor Macrocyclic Lactones, Compositions and Methods of Use'', to 
Attenuon, L.L.C., having a place of business in San Diego, CA. The 
aforementioned patent rights have been assigned to the United States of 
America.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before May 24, 
2002, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Wendy R. Sanhai, Ph.D., Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; e-mail: [email protected]; 
Telephone: (301) 496-7056, ext. 244; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: This invention describes a class of 
macrocyclic lactones (benzolactone enamides) derived from marine 
sponges, and which inhibit vacuolar-type (H\+\) ATPases (V-ATPases). 
Selective inhibition of V-ATPases may represent an effective means of 
treating various disease states: Alzheimer's disease, glaucoma and 
osteoporosis and cancer (via affecting cellular proliferation, 
angiogenesis, tumor cell invasiveness, metastasis and drug resistance). 
The compounds have been shown to be active against a specific group of 
human tumors when tested in the NCI 60-cell line panel. The licensee of 
these inventions will be required to comport with all applicable 
federal and country-of-collection policies relating to biodiversity.
    The field of use may be limited to the treatment of cancer, 
angiogenesis-dependent diseases and osteoporosis.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 14, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-7057 Filed 3-22-02; 8:45 am]
BILLING CODE 4140-01-P